FIELD OF APPLICATIONDETAILS
Generic Name
Efgartigimod Alfa and Hyaluronidase-qvfc
Active Ingredient
Efgartigimod Alfa and Hyaluronidase-qvfc
US Brand Names
Vyvgart Hytrulo
Drug Category
Neurology, Neuromuscular Agents
Drug Class
Neonatal Fc Receptor Blocker, Endoglycosidase Combination
Route of Administration
Subcutaneous Injection
FDA Approval Status
FDA Approved (June 20, 2023)
Approved

Efgartigimod Alfa and Hyaluronidase-qvfc Overview

Efgartigimod Alfa and Hyaluronidase-qvfc is a humanized immunoglobulin G1 antibody fragment combination prescription therapy used to treat adult patients with generalized myasthenia gravis or chronic inflammatory demyelinating polyradiculoneuropathy. Neurologists and neuromuscular specialists administer this targeted biological treatment via subcutaneous injection in outpatient clinics or specialized clinical settings.

What Is Efgartigimod Alfa and Hyaluronidase-qvfc & How Does It Work?

Efgartigimod Alfa and Hyaluronidase-qvfc is a co-formulated combination consisting of an engineered human IgG1 Fc fragment and recombinant human hyaluronidase. Hyaluronidase temporarily breaks down hyaluronan in the subcutaneous tissue, allowing rapid dispersion and absorption of the co-formulated Efgartigimod Alfa payload.

In generalized myasthenia gravis and chronic inflammatory demyelinating polyradiculoneuropathy, autoimmune pathogenic IgG antibodies attack nerve-muscle signals and peripheral nerve coatings. Efgartigimod Alfa binds to the neonatal Fc receptor with high affinity, preventing natural IgG recycling. Unbound disease-causing IgG antibodies are diverted to cellular lysosomes for degradation, dropping overall circulating IgG levels and restoring peripheral neuromuscular function.

Is Efgartigimod Alfa and Hyaluronidase-qvfc FDA Approved?

Yes, Efgartigimod Alfa and Hyaluronidase-qvfc are officially approved by the United States Food and Drug Administration.

What Is Efgartigimod Alfa and Hyaluronidase-qvfc Used For?

  • Treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive.
  • Treatment of chronic inflammatory demyelinating polyradiculoneuropathy in adult patients.

Before Taking Efgartigimod Alfa and Hyaluronidase-qvfc: Contraindications & Precautions

Your specialist team will review your active infection history and baseline immunization records prior to starting subcutaneous treatment.

Who Should Not Take This Medicine?

  • Anyone with a known severe hypersensitivity or allergic reaction to Efgartigimod Alfa, hyaluronidase, or any inactive ingredients in the solution.

Pregnancy & Fertility

  • Discuss pregnancy plans with your doctor; human data regarding Efgartigimod Alfa and Hyaluronidase-qvfc in pregnant women is limited.
  • Subcutaneous treatment causes temporary drops in maternal IgG levels, which can reduce passive antibody transfer across the placenta to the fetus during the third trimester.
  • It is unknown whether Efgartigimod Alfa or hyaluronidase passes into human breast milk.

Tell Your Doctor Before Taking This Medicine

  • Disclose any active viral, bacterial, or fungal infection, as treatment lowers protective IgG antibody levels.
  • Inform your provider if you have received live or live-attenuated vaccines recently or are scheduled for immunization.
  • Share if you have a history of severe kidney impairment or systemic autoimmune diseases.
  • Provide a complete list of all active prescription drugs, immunosuppressive therapies, and biologic medications.

Efgartigimod Alfa and Hyaluronidase-qvfc Dosage & Administration

Efgartigimod Alfa and Hyaluronidase-qvfc is supplied as a single-dose vial containing 1,008 mg Efgartigimod Alfa and 11,200 units hyaluronidase per 5.6 mL for subcutaneous injection.

Standard Dosing

  • Generalized Myasthenia Gravis Dosing: 1,008 mg / 11,200 units administered subcutaneously over approximately 30 to 90 seconds once weekly for 4 consecutive weeks.
  • CIDP Dosing: 1,008 mg / 11,200 units administered subcutaneously over approximately 30 to 90 seconds once weekly.
  • Subsequent Cycles: For myasthenia gravis, subsequent 4-week treatment cycles are administered based on clinical evaluation of symptom return.

How It Is Administered

  • Administered strictly by trained healthcare professionals in a clinic or healthcare setting into the abdomen.
  • Inject subcutaneously over 30 to 90 seconds using a syringe and winged infusion set.
  • Rotate injection sites across different quadrants of the abdomen for subsequent injections.

Efgartigimod Alfa and Hyaluronidase-qvfc Clinical Efficacy & Research

The FDA approval of this subcutaneous combination was supported by Phase 3 clinical trials, including the ADAPT-SC study in generalized myasthenia gravis and the ADHERE study in CIDP. Clinical trial results demonstrated that subcutaneous Efgartigimod Alfa and Hyaluronidase-qvfc produced total IgG reductions comparable to intravenous formulations, achieving fast clinical improvement in daily living scores. In CIDP, trial data confirmed a statistically significant reduction in relapse risk compared to placebo.

Efgartigimod Alfa and Hyaluronidase-qvfc Side Effects & Safety Profile

BLACK BOX WARNING

Efgartigimod Alfa and Hyaluronidase-qvfc currently does not carry an official FDA Boxed Warning.

Subcutaneous Efgartigimod Alfa and Hyaluronidase-qvfc delivers rapid antibody reduction, but these temporary drops in protective IgG levels require active safety monitoring. Because it suppresses part of the immune system, patients require proactive symptom management throughout the course of treatment.

Common Side Effects

  • Injection site reactions (redness, pain, bruising, swelling).
  • Upper respiratory tract infections and urinary tract infections.
  • Headache and migraine.
  • Muscle pain and joint discomfort.
  • Diarrhea and abdominal pain.

Serious Adverse Events

  • Severe or recurrent bacterial, viral, or fungal infections.
  • Severe systemic anaphylaxis or angioedema.
  • Significant temporary leukopenia or lymphopenia.

Managing Side Effects

If mild injection site redness occurs, apply a cold compress to the area. If you develop fever, chills, burning with urination, or signs of a severe allergic reaction, seek immediate medical evaluation.

Efgartigimod Alfa and Hyaluronidase-qvfc Drug Interactions & What to Avoid

Combining this medicine with drugs that depend on FcRn recycling or recent live vaccines alters safety and treatment efficacy.

Drug Interactions

  • Monoclonal Antibodies and IVIG: Efgartigimod Alfa speeds up the clearance of concurrent monoclonal antibodies and intravenous immunoglobulins; avoid co-administration.
  • Live or Live-Attenuated Vaccines: Live vaccines should be given at least 4 weeks prior to starting treatment or delayed until IgG levels recover.

Food & Alcohol

  • Food intake does not affect treatment because the drug is given subcutaneously.
  • Avoid excessive alcohol, as alcohol can worsen muscle weakness and fatigue.

Efgartigimod Alfa and Hyaluronidase-qvfc: Missed Dose, Overdose & Storage

Adhering to weekly subcutaneous injection schedules maintains steady IgG antibody clearance.

Missed Dose

If a scheduled weekly injection is missed, administer the dose as soon as possible (up to 3 days after the scheduled date), then resume the original weekly schedule. If more than 3 days have passed, skip the missed dose and continue with the next scheduled appointment.

Overdose & Emergency

An overdose causes rapid, profound drops in total serum IgG levels. Seek immediate medical evaluation in a hospital setting for monitoring.

How To Store It

  • Store unopened vials refrigerated between 2°C and 8°C (36°F and 46°F) in original carton to protect from light.
  • Do not freeze or shake vials.
  • May be stored at room temperature up to 30°C (86°F) for a single period of up to 30 days in original carton.

Efgartigimod Alfa and Hyaluronidase-qvfc Patient Management & Monitoring

Your neurology team will assess your muscle strength scores, antibody levels, and infection signs before each treatment cycle.

Tests Before Starting

  • Confirmed diagnosis of anti-AChR positive myasthenia gravis or CIDP.
  • Baseline clinical evaluation using MG-ADL or CIDP disability scales.
  • Baseline screening for active infections and serum immunoglobulin IgG level check.

Monitoring During Routine Use

  • Routine monitoring for signs and symptoms of infection throughout treatment.
  • Observation for hypersensitivity or injection site reactions after each subcutaneous dose.
  • Periodic re-evaluation of motor function and daily living scores.

Do’s And Don’ts

  • Do report any signs of fever, cough, or infection to your doctor immediately.
  • Do rotate injection sites across your abdomen for each weekly dose.
  • Don’t receive live vaccines while undergoing active treatment.
  • Don’t rub or massage the injection site immediately after receiving the dose.

Frequently Asked Questions

What is this medicine used for?

It is a prescription subcutaneous injection used to treat generalized myasthenia gravis in adults who are anti-AChR antibody positive and adults with chronic inflammatory demyelinating polyradiculoneuropathy.

How does this drug work?

It blocks the neonatal Fc receptor, preventing it from recycling antibodies. This causes the body to rapidly break down disease-causing IgG antibodies, improving muscle and nerve function.

How is this medication administered?

It is given as a quick subcutaneous injection into the abdomen over 30 to 90 seconds by a healthcare provider in a clinic once a week.

How does this differ from standard Vyvgart?

Standard Vyvgart is given as a 1-hour intravenous infusion, whereas Vyvgart Hytrulo contains hyaluronidase and is given as a 30 to 90 second injection under the skin.

Can I get vaccinated while taking this medicine?

You should complete non-live vaccinations before starting treatment. Live vaccines are not recommended during treatment because lowering IgG levels can reduce vaccine response or increase infection risks.

What are the most common side effects?

The most common side effects include injection site reactions like redness or pain, upper respiratory infections, headaches, and muscle pain.

How quickly does the injection work?

Many patients begin to notice improvements in muscle strength or nerve symptoms within 1 to 2 weeks after starting their weekly injection schedule.

References

  • U.S. FDA prescribing information for Vyvgart Hytrulo (Efgartigimod Alfa and Hyaluronidase-qvfc) injection
  • U.S. FDA Drugs@FDA drug approval overview (Application No. 761304)
  • American Academy of Neurology Practice Guidelines for Generalized Myasthenia Gravis and CIDP
  • Myasthenia Gravis Foundation of America Clinical Overview of Subcutaneous FcRn Inhibitors

The information provided is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider at any hospital or any local clinic before starting or stopping any medication.